[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE264666T1 - Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe - Google Patents

Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe

Info

Publication number
ATE264666T1
ATE264666T1 AT99947537T AT99947537T ATE264666T1 AT E264666 T1 ATE264666 T1 AT E264666T1 AT 99947537 T AT99947537 T AT 99947537T AT 99947537 T AT99947537 T AT 99947537T AT E264666 T1 ATE264666 T1 AT E264666T1
Authority
AT
Austria
Prior art keywords
resident
stomach
medicinal
active ingredients
delayed release
Prior art date
Application number
AT99947537T
Other languages
English (en)
Inventor
Gerard Alaux
Frederic Andre
Alain Cuine
Gareth Lewis
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE264666T1 publication Critical patent/ATE264666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99947537T 1998-10-16 1999-10-12 Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe ATE264666T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9812977A FR2784583B1 (fr) 1998-10-16 1998-10-16 Composition pharmaceutique a residence gastrique et a liberation controlee
PCT/FR1999/002443 WO2000023045A1 (fr) 1998-10-16 1999-10-12 Composition pharmaceutique a residence gastrique et a liberation controlee

Publications (1)

Publication Number Publication Date
ATE264666T1 true ATE264666T1 (de) 2004-05-15

Family

ID=9531635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947537T ATE264666T1 (de) 1998-10-16 1999-10-12 Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe

Country Status (12)

Country Link
US (1) US6861072B1 (de)
EP (1) EP1121099B1 (de)
JP (1) JP2002527464A (de)
AT (1) ATE264666T1 (de)
AU (1) AU774723B2 (de)
CA (1) CA2347105C (de)
DE (1) DE69916640T2 (de)
DK (1) DK1121099T3 (de)
ES (1) ES2219062T3 (de)
FR (1) FR2784583B1 (de)
PT (1) PT1121099E (de)
WO (1) WO2000023045A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
EP1411901B1 (de) 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
ES2247897B1 (es) * 2003-12-18 2007-05-01 Gat Formulation Gmbh Tabletas con matriz polimerica emulsionada para emision controlada de gases y procedimiento para su fabricacion.
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
EP1957052A2 (de) * 2005-10-25 2008-08-20 Pharmascience Inc. System zur abgabe eines magenretentionsmittels
US7879355B2 (en) * 2005-11-08 2011-02-01 Plensat Llc Method and system for treatment of eating disorders
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US20110112383A1 (en) * 2005-11-08 2011-05-12 Plensat, Inc Devices, systems and methods for treatment of eating disorders
US8206742B2 (en) * 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
SG170826A1 (en) 2006-04-04 2011-05-30 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an acid inhibitor
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
JP2012500230A (ja) 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
KR101137466B1 (ko) * 2009-06-12 2012-04-20 안국약품 주식회사 염산 알푸조신 함유 서방성 정제
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2967352B1 (fr) * 2010-11-12 2012-12-28 Unither Dev Comprime effervescent pour l'administration par voie orale de principes actifs
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
EP3720434A4 (de) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. Nicht-racemische gemische und deren verwendung
BR112021024380A2 (pt) 2019-06-04 2022-04-19 Sunovion Pharmaceuticals Inc Formulações de liberação modificadas e usos das mesmas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
EP0814772B1 (de) * 1995-03-17 2001-07-18 The Boots Company PLC Pharmazeutische zusammensetzungen mit pektin
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
ES2159400T3 (es) * 1996-08-29 2001-10-01 Sanofi Synthalabo Comprimido con liberacion controlada de clorhidrato de alfuzosina
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
DE69828289T2 (de) * 1997-08-11 2005-06-02 Alza Corp., Mountain View Dosierungsform für verzögerte Freisetzung eines Wirkstoffs

Also Published As

Publication number Publication date
EP1121099B1 (de) 2004-04-21
JP2002527464A (ja) 2002-08-27
ES2219062T3 (es) 2004-11-16
AU774723B2 (en) 2004-07-08
PT1121099E (pt) 2004-08-31
DE69916640T2 (de) 2005-03-31
US6861072B1 (en) 2005-03-01
DE69916640D1 (de) 2004-05-27
DK1121099T3 (da) 2004-08-09
CA2347105A1 (en) 2000-04-27
WO2000023045A1 (fr) 2000-04-27
FR2784583B1 (fr) 2002-01-25
CA2347105C (en) 2009-09-29
FR2784583A1 (fr) 2000-04-21
EP1121099A1 (de) 2001-08-08
AU6094799A (en) 2000-05-08

Similar Documents

Publication Publication Date Title
ATE264666T1 (de) Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe
DE69918310D1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
PT795324E (pt) Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
NO995313L (no) Mikroartikler nyttige som ultrasoniske kontrastmidler og til levering av legemidler i blodbanen
ATE300286T1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
DE69428862D1 (de) Linsenförmig pharmazeutische Tablette mit verzögerter Freigabe
WO2002013784A3 (en) Drug delivery system with bilayer electrodes
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
ES2166781T3 (es) Preparados farmaceuticos para el tratamiento selectivo de la enfermedad de crohn y colitis ulcerosa.
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
ATE367803T1 (de) Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
WO2001013899A3 (de) Wirkstoffhaltiges therapeutisches system mit mindestens zwei polymerhaltigen schichten
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
WO2005007137A3 (de) Ambroxolhaltige tabletten
ATE306910T1 (de) Tablette mit verlängerter wirkstoffabgabe im magen
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
ATE213933T1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff
WO1998009623A3 (en) Use of cholinergic drugs
WO2003096968A3 (en) Oral osmotic controlled drug delivery system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121099

Country of ref document: EP